Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva-lon underscores the innovation message

This article was originally published in Scrip

Executive Summary

When Teva came in with its $81.50 per share, $6.6 billion offer to buy Cephalon on 2 May, it was offering $8.50 a share more than Cephalon's hostile suitor, the Canadian specialty pharma company, Valeant. So the question is, where does Teva find around $600 million of extra value within a company 40% of whose $2.8 billion in revenues in 2010 is under threat as patents on its lead product, Provigil, expire.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts